ARTARA THERAPEUTICS
Updated 418 days ago
1 Little West 12th Street, NY NY 10014
Biotech at its best is a profession of compassion. We are driven by the question, "how will this help the patients we serve?"... Our lead program is TARA 002, an investigational cellular therapy based on OK-432, an immunostimulant currently approved in Japan and Taiwan, that has been standard of care in LMs for over 20 years. Lymphatic malformations are rare, non-malignant masses that primarily form in the head and neck region of children before the age of two. Radiographically, lymphatic malformations have been categorized into three subtypes - macrocystic, microcystic, or mixed (a combination of the other two). In the US and Europe, the standard of care is surgical excision, which is associated with high rates of recurrence and complications.1 A US-based, multicenter study in more than 600 patients, led by the University of Iowa, demonstrated that OK-432, was safe and effective in the treatment of macrocystic and mixed LMs... We believe Arya Tara reflects our personal and corporate..
Also known as: ArTara Therapeutics, Inc.